Clinical Trials Browser

Myelodysplastic Syndromes × AP 1903 reagent × Lymphoid × Clear all

Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03733249 2023-09-26

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Phase 1/2 Terminated

187 enrolled 8 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Primary Immunodeficiency Diseases, Cytopenia, Anemia, Anemia, Aplastic, Anemia, Sickle Cell, Fanconi Anemia, Hemoglobinopathies, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Thalassemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Anemia, Diamond-Blackfan, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01744223 2022-07-12

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Phase 1/2 Active not recruiting

36 enrolled

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02477878 2022-07-12

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Phase 1 Active not recruiting

10 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT03301168 2022-07-12

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Phase 1/2 Active not recruiting

120 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Primary Immunodeficiency Diseases, Cytopenia, Anemia, Aplastic, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Osteopetrosis, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03459170 2022-07-12

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Phase 1 Active not recruiting

15 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasm, Residual, Hematologic Neoplasms

NCT02487459 2020-10-05

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Phase 1/2 Terminated

3 enrolled 15 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

Clinical Trials

DOTTI

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene